Log In
Print
BCIQ
Print
Print this Print this
 

Lonasen, blonanserin (AD-5423)

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionCombined dopamine D2 and serotonin (5-HT2) receptor antagonist
Molecular Target Dopamine D2 receptor ; Serotonin (5-HT2) receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today